Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12622001218785
Ethics application status
Approved
Date submitted
8/09/2022
Date registered
9/09/2022
Date last updated
16/06/2024
Date data sharing statement initially provided
9/09/2022
Type of registration
Prospectively registered

Titles & IDs
Public title
Effect of digital Cognitive Behavioural Therapy for insomnia (dCBTi) in people with co-morbid insomnia and sleep apnoea: A randomised waitlist controlled trial.
Scientific title
Effect of digital Cognitive Behavioural Therapy for insomnia (dCBTi) in people with co-morbid insomnia and sleep apnoea: A randomised waitlist controlled trial.
Secondary ID [1] 307946 0
Nil Known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Insomnia disorder 327600 0
Sleep Apnoea 327607 0
Condition category
Condition code
Mental Health 324687 324687 0 0
Other mental health disorders
Respiratory 324688 324688 0 0
Sleep apnoea
Neurological 324694 324694 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Name: Digital Cognitive Behavioural Therapy for insomnia (dCBTi).

Rationale: Cognitive behavioural therapy for insomnia (CBTi) is the recommended 'first line' treatment for insomnia (Qaseem et al., 2016, Ann Intern Med). CBTi is effective in people with co-morbid insomnia and sleep apnoea (Sweetman et al., 2019; Sleep). Very few Australian patients with insomnia ever access CBTi (Miller et al., 2017, JCSM). This project aims to test the effectiveness of a dCBTi intervention in people with co-morbid insomnia and sleep apnoea.

Type: Non-drug, online, interactive.

Setting/location: Online, any location in Australia.

Duration: 5 x 20 minute online sessions, delivered over 5 consecutive weeks.

Protocol: This program is based on CBTi, the recommended treatment for insomnia (e.g. Qaseem et al., 2016, Ann Intern Med, DOI: 10.7326/M15-2175). It is a digitised version of a brief CBTi protocol described in an scientific article in the Australian Journal of General Practice (Sweetman et al., 2021, AJGP, doi: 10.31128/AJGP-04-20-5391).

Content: Each session will be administered online (computer or mobile phone). Each session will contain videos, text, and images. Participants will be asked to enter text-based, numerical (e.g. minutes of sleep duration) and multiple-choice data throughout the program. Participants will receive tailored therapy recommendations during each weekly session (see Sweetman et al., 2021, Aus J General Practice for tailored therapy recommendations). Immediately after each session is completed, participants will receive an automated follow-up email with session-specific 'follow-up' information and tailored therapy recommendations including recommended bedtime window (approximate reading time: 15 minutes). Participants will receive another automated email one week later with a link to start each subsequent session. Videos are presented by researchers, psychologists, and sleep technicians, each with extensive experience (>8 years) in the management of insomnia.

Tailoring / personalisation: Therapy recommendations will be tailored to participant's insomnia symptoms at baseline and weekly changes in symptoms throughout the program. Bedtime Restriction Therapy (initial restriction of time in bed to consolidate sleep, and subsequent gradual extension of time in bed) is a core component of CBTi. Bedtime restriction recommendations will be tailored to the specific sleep/wake information that participants provide.

Primary therapeutic components: Information about sleep, Bedtime restriction therapy, Stimulus Control Therapy.

Adherence assessment: Adherence will be defined as the number of participants commencing each of the 5 online sessions. This information is automatically collected through the online system.
Intervention code [1] 324402 0
Treatment: Other
Intervention code [2] 324403 0
Behaviour
Comparator / control treatment
Waitlist control for 8 weeks before commencing dCBTi.

Participants in the waitlist condition will receive weekly emails with written information about insomnia and sleep health for the first 5 weeks of the trial. This includes information about;
- 'sleep hygiene' (healthy sleep behaviours)
- sleep myths and facts
- Information about caffeine and sleep
- depression and sleep
- chronic insomnia (symptoms, diagnosis, treatment options)

Each weekly information packet takes approximately 4 minutes to read.
Control group
Active

Outcomes
Primary outcome [1] 332505 0
Between-group change in self-reported insomnia severity on the Insomnia Severity Index (ISI) questionnaire.
Timepoint [1] 332505 0
Between-group change in ISI scores from baseline to 8-week follow-up (primary timepoint). Change in ISI scores from baseline to 16-week and 24-week follow-up in the CBTi group.
Secondary outcome [1] 413768 0
Between-group change in self-reported depression symptoms on the Patient Health Questionnaire (PHQ-9).
Timepoint [1] 413768 0
Between-group change in PHQ-9 scores from baseline to 8-week follow-up (primary timepoint). Change in PHQ-9 scores from baseline to 16-week and 24-week follow-up in the CBTi group.
Secondary outcome [2] 413769 0
Between-group change in self-reported anxiety symptoms on the Generalised Anxiety Disorder (GAD-7) questionnaire.
Timepoint [2] 413769 0
Between-group change in GAD-7 scores from baseline to 8-week follow-up (primary timepoint). Change in GAD-7 scores from baseline to 16-week and 24-week follow-up in the CBTi group.

Eligibility
Key inclusion criteria
Patient Inclusion Criteria
1. Adults aged great than or equal to 18 years.
2. Reliable access to computer, tablet or smartphone, with internet access
3. Basic English language comprehension as required for dCBTi program
4. An ISI score of at least 15 (Moderate insomnia)
5. Previous doctor-diagnosed Sleep Apnoea (assessed via self-report)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Psychiatric condition (Bi-polar disorder, schizophrenia)
2. Risk of suicide (PHQ-9; item 9 score of greater than or equal to 1)
3. Epilepsy
4. Currently pregnant
5. Moderate daytime sleepiness (Epworth Sleepiness Scale score equal to or more than 16)
6. People who are commercial drivers or operate heavy machinery for work
7. People with a cognitive impairment
8. Shift workers
9. Previous diagnosis of a sleep disorder other than insomnia and sleep apnoea
10. Previous sleepiness-related motor-vehicle accident


Based on presenting symptoms, potential participants who are not eligible for this trial will be directed to a specialist Insomnia Treatment Program to access CBTi delivered by experienced 'sleep' Psychologists, their general practitioner, or alternative digital CBTi program.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
No allocation concealment will be used.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation (1:1) using a randomisation table created by computer software (i.e. computerised sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Participants in the waitlist control condition will be provided written material on insomnia an sleep health for the first 5-weeks of the trial (education control), and will be provided access to the dCBTi program following the 8-week follow-up.

Additional follow-up questionnaire assessments will be collected at 16-weeks, and 24-weeks post-randomisation.
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Sample size is designed to generate effect sizes and variability measures needed to power a future Randomised Controlled Trial.

Linear Mixed Models will be used to investigate the between-group difference in change in ISI scores from baseline to 8-week follow-up.

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
30/09/2022
Actual
23/09/2022
Date of last participant enrolment
Anticipated
Actual
16/05/2024
Date of last data collection
Anticipated
31/10/2024
Actual
Sample size
Target
30
Accrual to date
Final
30
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC

Funding & Sponsors
Funding source category [1] 312213 0
Self funded/Unfunded
Name [1] 312213 0
NA
Country [1] 312213 0
Primary sponsor type
University
Name
Flinders University
Address
The Adelaide Institute for Sleep Health
Flinders University
Box 6, Level 2A Mark Oliphant Building
5 Laffer Drive
Bedford Park, 5042, South Australia
Country
Australia
Secondary sponsor category [1] 313741 0
None
Name [1] 313741 0
Address [1] 313741 0
Country [1] 313741 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 311594 0
Southern Adelaide Human Research Ethics Committee
Ethics committee address [1] 311594 0
Ethics committee country [1] 311594 0
Australia
Date submitted for ethics approval [1] 311594 0
25/08/2022
Approval date [1] 311594 0
20/09/2022
Ethics approval number [1] 311594 0
2022/HRE00217

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 121650 0
Dr Alexander Sweetman
Address 121650 0
Adelaide Institute for Sleep Health, Mark Oliphant Building, Level 2A 5 Laffer Drive, Bedford Park, 5042 Flinders University South Australia
Country 121650 0
Australia
Phone 121650 0
+61 8 7421 9908
Fax 121650 0
Email 121650 0
alexander.sweetman@flinders.edu.au
Contact person for public queries
Name 121651 0
Alexander Sweetman
Address 121651 0
Adelaide Institute for Sleep Health, Mark Oliphant Building, Level 2A 5 Laffer Drive, Bedford Park, 5042 Flinders University South Australia
Country 121651 0
Australia
Phone 121651 0
+61 8 7421 9908
Fax 121651 0
Email 121651 0
alexander.sweetman@flinders.edu.au
Contact person for scientific queries
Name 121652 0
Alexander Sweetman
Address 121652 0
Adelaide Institute for Sleep Health, Mark Oliphant Building, Level 2A 5 Laffer Drive, Bedford Park, 5042 Flinders University South Australia
Country 121652 0
Australia
Phone 121652 0
+61 8 7421 9908
Fax 121652 0
Email 121652 0
alexander.sweetman@flinders.edu.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Not requested in participant information and consent forms (ethics).


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.